Last updated: August 16, 2026
Biorphen is a ready-to-use phenylephrine hydrochloride injection approved by the FDA for clinically significant hypotension caused by vasodilatory shock, particularly in the setting of anesthesia. Its commercial value comes from reducing bedside dilution, limiting medication-preparation steps, and supporting standardized dosing. The excipient system is deliberately simple: an aqueous vehicle with sodium chloride and citrate-based pH control. That composition supports rapid intravenous administration, but it also leaves commercial space for differentiated presentations, packaging, stability, and workflow features rather than major pharmacologic reformulation.
What is Biorphen and how is it used?
Biorphen contains phenylephrine hydrochloride, a direct alpha-1 adrenergic receptor agonist. The product is supplied as a ready-to-use intravenous injection at 0.1 mg/mL, eliminating the need to dilute a concentrated phenylephrine vial before administration.[1]
| Product attribute |
Biorphen profile |
| Active ingredient |
Phenylephrine hydrochloride |
| Pharmacologic class |
Alpha-1 adrenergic agonist |
| Route |
Intravenous injection |
| Strength |
0.1 mg/mL |
| Main use |
Hypotension associated with vasodilatory shock, including anesthesia-related hypotension |
| Regulatory pathway |
FDA 505(b)(2) application |
| Dosage form |
Sterile aqueous injection |
| Primary commercial advantage |
Ready-to-use presentation |
The product competes with generic phenylephrine hydrochloride injections, including concentrated products that require dilution and administration from a syringe or infusion system. Biorphen's commercial positioning is based on preparation efficiency and medication-safety economics, not on a new active pharmaceutical ingredient.
What excipients are used in Biorphen?
The Biorphen formulation uses a conventional parenteral excipient platform:
- Water for injection as the vehicle.
- Sodium chloride for isotonicity.
- Sodium citrate and citric acid for buffering and pH adjustment.
The FDA label identifies Biorphen as a sterile, clear, colorless solution with a target acidic pH suitable for phenylephrine hydrochloride stability.[1] The excipient system avoids preservatives and complex surfactant technology, which is appropriate for a single-dose injectable product.
Why does Biorphen use sodium chloride?
Sodium chloride adjusts tonicity and helps produce an injectable solution compatible with intravenous administration. An isotonic or near-isotonic product is commercially preferable in operating rooms and intensive-care units because it reduces the need for additional dilution and limits concerns about local irritation or fluid-balance effects.
The formulation opportunity is limited by the need to preserve:
- Chemical stability of phenylephrine.
- Clarity and absence of visible particles.
- Compatibility with glass vials, elastomeric closures, syringes, and infusion equipment.
- Acceptable osmolality and pH.
- Sterility through the labeled shelf life.
Why are citrate excipients commercially important?
Phenylephrine is susceptible to degradation pathways affected by pH, oxygen, light, temperature, and trace metals. Citrate buffering can help maintain the formulation in a stability-favorable acidic range. It also permits pH control without relying on a more complex excipient package.
For a generic or follow-on developer, copying the active ingredient concentration is relatively straightforward. Reproducing the same stability profile in a commercially robust container-closure system is more important. The key development variables include buffer concentration, dissolved oxygen, headspace, container permeability, sterilization conditions, and light exposure.
What excipient strategies could differentiate a Biorphen competitor?
A competing product does not need a radically different excipient system. The strongest strategy is to improve administration, stability, or packaging while preserving phenylephrine's established clinical profile.
Ready-to-use syringe
A prefilled syringe could extend Biorphen's preparation advantage. It may reduce transfer steps, dose calculation, and syringe preparation time. The development burden includes:
- Syringe-material compatibility.
- Extractables and leachables.
- Plunger integrity.
- Glide force and break-loose force.
- Sterility assurance.
- Stability during shipping and storage.
- Device-human factors validation.
A prefilled syringe can command a price premium over a vial, but hospitals may resist the premium if their pharmacy systems already prepare phenylephrine centrally.
Larger-volume infusion presentation
A 50 mL or 100 mL ready-to-use bag could target continuous infusion in intensive-care settings. This format would compete less directly with anesthesia syringes and more directly with compounded or pharmacy-prepared infusions.
The excipient system would require assessment of:
- Phenylephrine adsorption to bag materials and tubing.
- Concentration changes during prolonged infusion.
- Compatibility with common infusion pumps.
- Particulate formation.
- In-use stability after line connection.
- Light protection during administration.
A bag presentation could create a separate commercial segment, but it may require a new formulation and packaging package rather than a simple line extension.
Lower-concentration pediatric presentation
A lower-strength product could target pediatric and neonatal environments where dosing errors are more consequential. The opportunity is commercially attractive but technically and regulatorily sensitive. Developers would need to demonstrate dose accuracy, labeling clarity, compatibility with small-volume syringes, and a meaningful reduction in preparation errors.
The best excipient approach would retain the established saline-buffer platform. A new preservative or surfactant would add unnecessary regulatory and safety complexity.
Preservative-free multidose technology
A preservative-free multidose vial could reduce waste in high-throughput procedural settings. The barrier is sterility assurance after repeated withdrawals. Such a product may require a specialized closure or an advanced container system, creating a higher manufacturing and device-development burden.
What patents protect Biorphen and its formulation?
Biorphen's protection should be analyzed across four categories:
- Formulation patents covering phenylephrine concentration, pH, buffer composition, or stability.
- Container-closure patents covering a vial, syringe, or ready-to-use presentation.
- Manufacturing patents covering sterile filling, oxygen control, or packaging.
- Method-of-use patents covering treatment of anesthesia-associated hypotension or vasodilatory shock.
Biorphen was approved through the 505(b)(2) pathway, which can support regulatory exclusivity and reliance on previously established phenylephrine data.[2] The product's commercial barrier is likely to depend more heavily on FDA exclusivity, listed patents, formulation know-how, and manufacturing execution than on active-ingredient exclusivity.
What is the Orange Book status of Biorphen?
The Orange Book must be reviewed for the current listed patents, expiration dates, and exclusivity codes associated with the Biorphen application. The relevant review fields are:
| Orange Book item |
Commercial significance |
| Application number |
Identifies the approved 505(b)(2) product |
| Patent listing |
Determines whether a Paragraph IV certification may be required |
| Patent expiration |
Defines the potential listed-patent barrier |
| New chemical entity exclusivity |
Not expected for established phenylephrine |
| Three-year exclusivity |
May have applied to the approval of the new dosage form or clinical investigation |
| Pediatric exclusivity |
Extends applicable listed exclusivity by six months if granted |
Because phenylephrine is an established active ingredient, a generic applicant can generally pursue an ANDA where the reference-product and formulation requirements are met. A product relying on Biorphen's clinical or formulation bridge may instead require a 505(b)(2) application.
When does Biorphen lose exclusivity?
Biorphen's market protection is distinct from active-ingredient patent protection. Phenylephrine itself is an old drug, so the relevant questions are the expiration of any listed patents and the end of regulatory exclusivity tied to the approved presentation.
Biorphen received FDA approval in 2020. Any three-year exclusivity associated with new clinical investigations would not ordinarily provide a continuing barrier after 2023, although patent rights can extend beyond that period.[1][2]
A generic launch analysis should separate:
- FDA regulatory exclusivity.
- Listed patent expiration.
- Paragraph IV litigation.
- Formulation similarity.
- Manufacturing capacity.
- Hospital contracting cycles.
- Product shortages and supply reliability.
Which companies are challenging Biorphen?
A definitive challenger list requires current FDA Orange Book data, ANDA records, and court dockets. Publicly visible competition is more likely to arise from generic phenylephrine manufacturers than from biosimilar developers. Biorphen is a small-molecule injectable, so biosimilar risk does not apply.
Potential competitors include manufacturers of:
- Phenylephrine hydrochloride concentrated injection.
- Ready-to-use phenylephrine syringes.
- Pharmacy-compounded phenylephrine preparations.
- Other vasopressors, including norepinephrine and epinephrine.
A Paragraph IV challenge would be commercially credible if the challenger can argue that the asserted claims are invalid, not infringed, or not required for the proposed product. A formulation patent with narrow excipient or pH limitations may be vulnerable to design-around strategies using a different buffer concentration, container, or concentration.
How strong is the Biorphen patent estate?
The estate is strongest if it covers a commercially essential combination rather than a narrow laboratory formulation. Claims directed only to sodium chloride and citrate in an acidic phenylephrine solution may face design-around pressure because injectable developers can alter buffer ratios, pH ranges, concentrations, or packaging.
The most durable claim categories would cover:
- A defined phenylephrine concentration with demonstrated long-term stability.
- A ready-to-administer product with a specific container-closure system.
- Oxygen-controlled manufacturing and storage.
- Compatibility with infusion devices.
- A clinically relevant reduction in preparation steps or dosing errors.
Manufacturing know-how can remain commercially valuable even when patent protection is narrow. Sterile injectable production has high entry costs, and regulatory approval depends on process validation, aseptic controls, analytical methods, and reliable supply.
What commercial opportunities exist for Biorphen excipients?
The principal opportunities are line extensions and hospital-workflow products rather than new therapeutic indications.
| Opportunity |
Commercial rationale |
Main barrier |
| Prefilled syringe |
Reduces preparation and dosing steps |
Device cost and human-factors work |
| Ready-to-use infusion bag |
Targets intensive-care infusion |
Stability and material compatibility |
| Pediatric strength |
Improves dose handling |
Safety, labeling, and small-market economics |
| Extended shelf life |
Reduces inventory waste |
Long-term stability package |
| Light-protective packaging |
Supports storage and administration control |
Packaging cost |
| Emergency-department kit |
Simplifies rapid access |
Procurement and inventory integration |
| Contract-manufactured hospital presentation |
Supports institutional purchasing |
Scale and sterile capacity |
The most immediate opportunity is a prefilled syringe using the existing saline-citrate platform. The highest-value opportunity may be a ready-to-use infusion bag if it can demonstrate stable concentration, broad device compatibility, and lower total preparation cost.
How does Biorphen compare with generic phenylephrine injections?
Biorphen's differentiation is operational. Generic concentrated phenylephrine may have a lower acquisition price, but the hospital must account for pharmacy labor, dilution materials, labeling, medication-error risk, and time to administration.
A total-cost analysis should quantify:
- Pharmacy preparation time per dose.
- Nursing administration time.
- Waste from partially used vials.
- Medication-error events and near misses.
- Stockout frequency.
- Product wastage after opening.
- Premium paid for ready-to-use packaging.
Biorphen is most defensible in settings where rapid administration, standardized dosing, and reduced preparation are valued. It is less defensible where hospitals have automated compounding infrastructure and strong price controls.
What litigation and generic-entry risks affect Biorphen?
The principal risks are formulation-patent litigation, an authorized generic, and substitution by lower-priced phenylephrine products. A successful Paragraph IV challenge could accelerate entry before the end of the listed-patent term. Even without litigation, hospitals may substitute concentrated generic products if supply and preparation controls are adequate.
Commercial risk is highest when:
- The product depends on one sterile manufacturer.
- A competitor offers a lower-cost prefilled syringe.
- A hospital system standardizes on norepinephrine or another vasopressor.
- The formulation has limited room-temperature stability.
- The product's price premium exceeds measurable workflow savings.
Key Takeaways
- Biorphen is a ready-to-use phenylephrine hydrochloride injection approved through the FDA 505(b)(2) pathway.
- Its excipient strategy is conventional and commercially rational: water for injection, sodium chloride, and citrate-based pH control.
- The principal product advantage is reduced preparation burden, not novel pharmacology.
- The strongest line-extension opportunity is a prefilled syringe; a ready-to-use infusion bag offers a larger but more technically demanding opportunity.
- Biorphen has no biosimilar risk because phenylephrine is a small molecule.
- Generic-entry risk depends on current Orange Book listings, patent scope, formulation design-around options, and sterile manufacturing capacity.
- Hospital procurement economics will determine whether Biorphen's ready-to-use format supports a durable price premium.
FAQs
Can a competitor use different excipients from Biorphen?
Yes. A competitor may use a different buffer or tonicity agent if the product meets FDA requirements for stability, sterility, safety, compatibility, and performance.
Is Biorphen a biologic drug?
No. Biorphen contains phenylephrine hydrochloride, a synthetic small-molecule active ingredient. Biosimilar approval and biosimilar interchangeability rules do not apply.
What excipient is most important for Biorphen stability?
The citrate-based pH-control system is central because phenylephrine stability depends heavily on formulation pH and control of degradation conditions.
Could Biorphen be reformulated as a preservative-containing product?
Technically possible, but a preservative would introduce added toxicology, compatibility, labeling, and regulatory requirements. A preservative-free single-dose presentation is commercially cleaner.
What is the best commercial route for a Biorphen follow-on product?
A ready-to-use prefilled syringe is the most direct route. It builds on the same workflow benefit while creating differentiation through device design, dose accuracy, packaging, and hospital-use economics.
References
- U.S. Food and Drug Administration. (2020). Biorphen (phenylephrine hydrochloride injection) prescribing information. FDA.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
- U.S. Food and Drug Administration. (2024). Guidance for industry: Applications covered by section 505(b)(2). FDA.
